Holmium laser therapy for benign prostatic hyperplasia
Three abstracts were presented on holmium laser therapy for the treatment of benign prostatic hyperplasia (BPH). Rainer and co-workers reported 1-y follow-up data from a study comparing holmium laser enucleation of the prostate (HoLEP) with transurethral resection of the prostate (TURP). A total of 200 urodynamically obstructed patients participated in the study: 100 patients were randomised to HoLEP and 100 to TURP. A total of 194 patients completed the 1-y follow-up assessment. HoLEP was performed with high-powered holmium : YAG laser at 80-100 W (2.0 J, 40-50 Hz) and 550 nm bare laser fibres. American Urological Association (AUA) symptom scores, peak urinary flow rates and postvoid residual urine volumes were evaluated, preoperatively, and at 1, 6 and 12 months postoperatively. Mean patient age was 68.0 and 68.7 y for the HoLEP and TURP patients, respectively. Prostate volume was 53.5 g (range 20-95 g) vs 49.9 g (20-99 g); resected prostate tissue weight was 32.6 g (10-88 g) vs 37.2 g (10-102 g) for HoLEP and TURP patients, respectively. Both, HoLEP and TURP, resulted in lasting, pronounced and significant postoperative improvements of AUA symptom scores, peak urinary flow rates (Qmax) and postvoid residual urine volumes. The differences between the HoLEP and the TURP group were not significant at any postoperative interval. Although HoLEP had a longer operation time than TURP, it was associated with less blood loss, a lower complication rate, a shorter catheter time and hospital stay. The presenters concluded that HoLEP appears to be an acceptable alternative to TURP.
Varol and co-workers reported on the use of holmium laser enucleation of the prostate in 156 patients with BPH using the mushroom technique. Laser resection began with a bilateral bladder neck incision, which was extended to the verumontanum. The median lobe was resected to the bladder neck and left attached by a narrow mushroom-like pedicle. Following disconnection of the blood supply, the lobe was loop resected. The enucleation of the lateral lobe started at the level of the verumontanum, then along a laterally convex line towards the bladder leaving a narrow pedicle. The devascularised lobe was again loop resected. No significant blood loss in any patient or signs of TUR syndrome were reported. Follow-up in 125 patients showed a reduction in International Prostate Symptom Score (IPSS) from a median of 20 at baseline to 3 at 6 months and this remained stable at 24 months. Median increase in Qmax was from 8 to 20 ml/s at 6-24 months.
The third abstract was presented by Tan et al and included 7-y follow-up on high-powered holmium laser ablation (HoLAP). A total of 75 patients who had undergone HoLAP between November 1994 and May 1995 were contacted and asked to complete an AUA symptom score, single question quality of life (QOL), International Continence Society (ICS) male SF questionnaire and questions on potency. Flow rate and complications were also assessed. Minimum follow-up was 7.1 y. Preoperatively, mean age was 67.9 y, mean transrectal ultrasonography (TRUS) volume 39.8 g, mean AUA symptom score 18.8 and mean Qmax 9.9 ml/s. A total of 32 patients completed the assessment and of these four patients underwent a reoperation. Mean values were as follows: AUA score 10.2, QOL score 2.1, Qmax 16.1 ml/s, ICS voiding score 5.8 and ICS male IS 3.2. The impact of their current lower urinary symptoms (ICS QOL) was 0.68, implying minimal impact. Together with the total lack of pad use for incontinence, these results indicate the long-term benefits of HoLAP.
Radiotherapy for prostate cancer
Several abstracts reported results with prostate brachytherapy, which has been recently introduced in New Zealand and Australia. Matthews and associates (New Zealand) reported on their first 147 patients treated with transperineal permanent I125 seed implantation (TPSI). The majority of patients were T1 (n ¼ 137), with a mean prostate-specific antigen (PSA) level of 6.7 ng/ml and Gleason score (GS) o6 (n ¼ 26), GS ¼ 6 (n ¼ 105) and GS ¼ 7 (n ¼ 16). The median V100 (volume of the prostate receiving 100% of the planned dose) in the first 25 implants was 91% (overall 90%); median D90 (dose to 90% of the prostate) in the first 25 implants was 146 Gy (overall 146 Gy). A total of 7.5% of patients required intermittent self-catheterisation (mean duration 4.5 weeks; two patients still catheterised at 12 and 17 months). Late (41 y) Grade 3 urinary toxicity occurred in 6.5% of patients. No Grade 3 or 4 bowel toxicity was reported. It was concluded that TPSI procedures can be introduced with a minimal learning curve to produce toxicity levels equivalent to those from other international groups.
Stricker and co-workers (Australia) reported a series of 130 patients with localised prostate cancer treated with I125 implantation. Strict criteria for patient selection were used including PSA o10 ng/ml, Gleason score o7, oT2B, prostate volume o40 ml, AUA symptom score o10. Post-therapy, no cases of retention or acute or chronic grade 3 or 4 bowel toxicity have been recorded; the rate of acute grade 3 or 4 genitourinary toxicity is 47% (no chronic cases). Erectile dysfunction developed in 20% of patients, with over 90% of these responding to Viagra. V90 dosimetry has improved with time and virtually all patients now receive a V90 of 120 Gy, with a large proportion receiving doses greater than 140 Gy. It was concluded that with careful patient selection, satisfactory outcome with minimal toxicity can be achieved with prostate brachytherapy for prostate cancer.
Diagnosis of prostate cancer: analysis of ejaculate
Ejaculate has been studied as means of identifying abnormalities reflecting malignant change in the prostate. Grubor et al presented data on the use of matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry in the analysis of ejaculate supernatants. A total of 41 ejaculate supernatants samples from 19 prostate cancer patients (Gp 1), nine men with negative TRUS biopsies for cancer (Gp 2) and 13 men aged o30 y without a family history of prostate cancer (Gp 3) were studied. All patients provided samples prior to TRUS-guided needle biopsy or at least 1 month after biopsy. All patients in Gp 2 had at least 12 core biopsies. Results showed three distinct clusters of proteins for the three groups of men. Five distinct proteins were identified in the prostate cancer patients and these are being studied further. These data provide exciting possibilities for the new diagnostic methods for prostate cancer.
PSA and E-cadherin in prostate cancer
A model of PSA overexpression has been developed based on the cell line PC-3 (Veveris-Lowe et al). The cell line was transfected with a vector containing both wildtype PSA and a mutant copy of PSA, which would act as control. Several functional assays were performed including MTT proliferation, Matrigel-coated invasion and migration. No difference in rate of proliferation was observed in PSA clones and controls, suggesting that PSA has little or no mitogenic activity. However, PSA clones appeared to be more invasive and have increased migration/motility than controls. Changes in morphology were also observed, as well as ability to adhere to culture dishes.
The editors note that PC3 produces urokinase, a serine protease that enhances migration. PSA is reported to increase urokinase expression, which may be a mechanism contributing to the enhanced invasive behaviour of the PSA clones.
Atresentan and bone remodelling in prostate cancer patients Nelson et al (J Urol 2003; 169: 114-119) have reported on the effects of the endothelin-A receptor antagonist, atresentan, on bone deposition, resorption markers and bone scan index in men with hormone refractory prostate cancer (HRPC). A double-blind, randomised, placebo controlled study involving 288 asymptomatic patients was conducted at 74 medical centres in the US, with randomisation to one of three treatment groups: 2.5 mg atrasentan, 10 mg atrasentan or placebo administered on a daily basis until disease progression. Results showed that at baseline, markers of bone deposition and bone resorption were elevated 1.4-to 2.7-fold above the respective upper limits of normal. Following treatment, patients in the placebo group had a 58% elevation in mean total alkaline phosphatase and a 99% elevation in mean bone alkaline phosphatase, whereas patients in the 10 mg atrasentan group maintained stable mean total values of both markers. N-telopeptides, C-telopeptides and deoxypyridinoline elevations from baseline were consistently less in patients receiving 10 mg atrasentan compared with placebo. Similar trends were observed in patients receiving 2.5 mg atrasentan. The changes observed in clinical bone scan studies paralleled the bone marker changes. It was concluded that atrasentan exhibits clinical activity in HRPC through the suppression of markers for biochemical and clinical progression.
Zoledronic acid and hormone-refractory prostate cancer
The US Food and Drug Administration (FDA) has recently approved the use of Zometa (zoledronic acid), a bisphosphonate, for the treatment of patients with documented bone metastases from solid tumours in conjunction with standard antineoplastic therapy (Cohen et al, Oncologist 2002; 7: 393-400) . In the case of prostate cancer, it should have progressed after treatment with at least one hormonal therapy. The recommended dose schedule is 4 mg infused over 15 min every 3-4 weeks.
Prostate cancer often metastasises to bone during disease progression and patients consequently have a high risk of developing skeletal complications, including pathological fractures, spinal cord compression and severe bone pain. Bisphosphonate therapy is widely used for the prevention of these complications in multiple myeloma and breast cancer. A recent multicentre, randomised study has now reported that bisphosphonates are a safe and effective therapy in patients with bone metastases from HRPC. Patients were assigned to zoledronic acid 4 mg i.v. (n ¼ 214), zoledronic acid 8 mg i.v. (subsequently reduced to 4 mg; n ¼ 221) or placebo (n ¼ 208) every 3 weeks for 15 months. Approximately 38, 28 and 31% in the zoledronic 4 mg, 8 mg and
What's hot in the prostate? M Gleave and CP Evans placebo groups, respectively, completed the study. More patients on placebo (44.2%) developed skeletal-related events than those on 4 mg (33.2%) or 8 mg (38.5%) zoledronic acid. Median time to first skeletal event was 321 days in the placebo group, 363 days in the 8 mg zoledronic acid group and not reached in the 4 mg zoledronic acid group. Urinary markers of bone resorption were significantly decreased in patients on zoledronic acid (either dose) compared with placebo (P ¼ 0.001). Pain and analgaesic scores were also better in the active treatment groups. However, there were no differences in disease progression, performance status or quality of life scores among the groups. With regard to safety, a 15-min infusion of the 4 mg dose was well tolerated, but the 8 mg dose was associated with renal function deterioration.
Outcome with salvage radiotherapy after radical prostatectomy Katz et al (J Clin Oncol 2003; 21: 483-489 ) report on the predictors of biochemical outcome following radiotherapy in patients with rising PSA after radical prostatectomy. A total of 150 received salvage 3D conformal radiotherapy alone or with neoadjuvant androgen deprivation; median follow-up was 42 months. The 4-y actuarial PSA relapse-free, distant metastasisfree survival and overall survival rates were 46, 83 and 95%, respectively. Multivariate analysis on 70 patients receiving radiation without androgen deprivation indicated that negative/close margins, absence of extracapsular extensions and presence of seminal vesicle invasion were independent predictors of PSA relapse after radiotherapy. The 4-y PSA relapse-free survival rate did not improve with neoadjuvant hormonal deprivation in patients with positive margins, extracapsular extension and no seminal vesicle invasion. However, it did improve rates when one or more of these variables were absent.
Rofecoxib and prostatitis
A study on the successful use of rofecoxib in chronic nonbacterial prostatitis has been published by Nickel and co-workers (J Urol 2003; 169: 1401-1405). A total of 161 patients were randomised to 6 weeks of therapy with 25 mg rofecoxib, 50 mg rofecoxib or placebo following a 1-week placebo run-in phase. End points included the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) (average pain score item 4 primary end point) and patient global assessment questions of pain, disease activity and response to therapy. A significant decrease from baseline was reported in NIH-CPSI total, domain and pain scores in all groups (no significant difference between groups). A trend was noted in the percentage of patients with a 25% (six point) improvement in total score. This was significantly greater in patients on rofecoxib than placebo. Patient global assessment of pain, response to therapy and disease activity also favoured rofecoxib over placebo. No or mild pain was reported in 79 and 59% of patients treated with 50 mg rofecoxib and placebo, respectively (Po0.005); equivalent numbers for improvement in quality of life were 56 and 27% (Po0.005). This preliminary study suggests that rofecoxib benefits men with chronic prostatitis/chronic pelvic pain syndrome.
European Association of Urology: Annual Congress
The XVIIIth congress of the European Association of Urology (EAU) took place in Madrid on 12-15 March and the following are series of selected abstracts presented at the meeting. All abstracts have been published in Eur Urol 2003; 2: 1-236.
Bicalutamide as adjuvant to radical prostatectomy
Fourcade et al (abstract 156, p 41) presented data form the Early Prostate Cancer (EPC) programme, which is the largest prostate cancer trial yet conducted. At a median follow-up of 3 y, bicalutamide (Casodex) 150 mg in addition to standard therapies of radical prostatectomy, radiotherapy, watchful waiting reduced the risk of objective progression by 42% compared with standard therapies alone (see et al, J Urol 2002; 168: 429-435) . A new analysis has been conducted which looks at the relative increase in the actual time to event (event time ratio (ETR)), where an ETR 41 signifies a benefit. The analysis was used on data from 4454 patients who underwent radical prostatectomy.
Adjuvant bicalutamide significantly reduced the risk of objective progression by 37% (P ¼ 0.0001) and hence increased progression-free survival (PFS) by 41% (ETR 1.41). The estimated time for 10% of patients to progress was 3.9 y in the placebo group and 5.4 y in the adjuvant bicalutamide group. Bicalutamide also significantly reduced the risk of PSA progression by 51% (Po0.0001) and in doing so significantly increased PSA PFS by 94% (ETR 1.94). The estimated time for 10% of patients to experience PSA progression was 1.1 y in the placebo group compared with 2.0 y in the adjuvant bicalutamide group. These benefits were found to be greatest in patients with poorest prognosis.
Zoledronic acid: inhibition of prostatic epithelial invasion in vitro
Montague et al (abstract 138, p 37) reported that zoledronic acid significantly inhibits prostate epithelial proliferation and migration in bone marrow, but has no demonstrable effect on cell/matrix binding or endothelial permeability. These effects were associated with significant alterations in the cytokine milieu. These in vitro studies were conducted using PC-3 cell lines, prostates epithelial cells from men with benign and malignant disease and human bone marrow stroma. The median PSA value in the 14 men who had had no previous chemotherapy was 41 ng/ml (Group I) and 122 ng/ml in the eight men who had had second-or third-line chemotherapy (Group II). A mean of 4.3 cycles of chemotherapy was delivered. In Groups I and II, 11 and two patients, respectively, revealed a PSA decrease of 450%. This decrease was 480% in seven patients in Group I. PSA responders had a higher baseline PSA level than nonresponders. Toxicity was mild, particularly with regard to cardiovascular side effects.
PDE isoenzymes in the prostate
Olmsted County Study: 9-y follow-up
The 9-y follow-up data from the Olmsted County Study of Urinary Symptoms and Health Status among Men were presented by Jacobsen et al (abstract 95, p 26). During 20 871 person-years of follow-up, 124 men had a first episode of acute urinary retention (AUR) (incidence 5.9/1000 person-years). In men with no to mild symptoms (IPSS ¼ 7), the incidence of AUR increased from 2.5/1000 person-years among men aged 40-49 y to 7.8/10 000 person-years in men aged 70-79 y. The equivalent rise in men with moderate to severe symptoms (IPSS 47) was from 3.4 to 23.0/1000 person-years. Men with an enlarged prostate (430 ml) experienced a 2.8-fold increased risk of AUR. Men with an elevated PSA or a depressed urinary flow rate also experienced increased risk of AUR. These data suggest that closer evaluation may be warranted in men with increased risk of AUR.
